Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 30MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 30MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides calories and serves as a source of glucose, which is metabolized to carbon dioxide and water, yielding energy. Sodium and chloride are major electrolytes that maintain osmolality and acid-base balance. Potassium is essential for nerve conduction, muscle contraction, and maintaining intracellular tonicity.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion; dose determined by individual patient requirements, fluid and electrolyte status, serum potassium concentration, and acid-base balance; typical adult rate: 100-200 mL/hour (up to 2 L/day) as maintenance fluid.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Glucose: 1.5–2 hours (endogenous); sodium and potassium follow body homeostatic regulation with no defined half-life in isolation.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: >95% as free glucose, sodium, and potassium. Biliary/fecal: <5%.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte